ATE316792T1 - Stimulierung wirtseigener abwehrmechanismen gegen krebs - Google Patents

Stimulierung wirtseigener abwehrmechanismen gegen krebs

Info

Publication number
ATE316792T1
ATE316792T1 AT97919564T AT97919564T ATE316792T1 AT E316792 T1 ATE316792 T1 AT E316792T1 AT 97919564 T AT97919564 T AT 97919564T AT 97919564 T AT97919564 T AT 97919564T AT E316792 T1 ATE316792 T1 AT E316792T1
Authority
AT
Austria
Prior art keywords
defense mechanisms
stimulation
host
against cancer
mechanisms against
Prior art date
Application number
AT97919564T
Other languages
English (en)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9765A external-priority patent/AUPN976596A0/en
Priority claimed from AUPO3959A external-priority patent/AUPO395996A0/en
Priority claimed from AUPO4387A external-priority patent/AUPO438796A0/en
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Application granted granted Critical
Publication of ATE316792T1 publication Critical patent/ATE316792T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97919564T 1996-05-09 1997-05-05 Stimulierung wirtseigener abwehrmechanismen gegen krebs ATE316792T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
AUPO3959A AUPO395996A0 (en) 1996-12-03 1996-12-03 Stimulation of host defence mechanisms
AUPO4387A AUPO438796A0 (en) 1996-12-24 1996-12-24 Method of treatment
US08/853,292 US6361769B1 (en) 1996-05-09 1997-05-09 Stimulation of host defense mechanisms against viral challenges

Publications (1)

Publication Number Publication Date
ATE316792T1 true ATE316792T1 (de) 2006-02-15

Family

ID=27424412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919564T ATE316792T1 (de) 1996-05-09 1997-05-05 Stimulierung wirtseigener abwehrmechanismen gegen krebs

Country Status (15)

Country Link
US (1) US6361769B1 (de)
EP (1) EP0906119B1 (de)
JP (1) JP3806445B2 (de)
CN (1) CN1151841C (de)
AT (1) ATE316792T1 (de)
AU (1) AU724689B2 (de)
BR (1) BR9709068A (de)
CA (1) CA2253971A1 (de)
DE (1) DE69735202T2 (de)
ES (1) ES2260791T3 (de)
ID (1) ID17768A (de)
IL (2) IL126971A0 (de)
NZ (1) NZ332689A (de)
TW (1) TW482676B (de)
WO (1) WO1997041884A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
ATE300952T1 (de) * 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
EP1602378A1 (de) * 1999-12-09 2005-12-07 Chiron Corporation Verfahren zur Verabreichung von Wirkstoffen in das zentrale Nervensystem oder Lymphsystem
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6415797B1 (en) * 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20050031587A1 (en) * 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
AU2003271175A1 (en) * 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
US20040136917A1 (en) * 2003-01-06 2004-07-15 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
US20050267144A1 (en) * 2003-01-06 2005-12-01 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
EP1757686A4 (de) * 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd Zelltodinduzierer
WO2005123112A2 (en) * 2004-06-12 2005-12-29 Pharma Pacific Pty Ltd. Method of enhancing the immune response to a vaccine
EP1870458B1 (de) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2-STRUKTURISOMERE
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20110044946A1 (en) * 2008-02-15 2011-02-24 Carter William A Genetec regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
CN102309758B (zh) * 2010-07-02 2013-02-20 北京凯因科技股份有限公司 一种治疗肠道病毒感染引起的疾病的药物组合物
US20130129678A1 (en) 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000588A1 (en) 1980-08-22 1982-03-04 Illinois Univ Delivery of biologically active components of heterologous species interferon isolates
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL76591A0 (en) 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
IL100332A0 (en) * 1990-12-14 1992-09-06 Schering Corp Oral administration of alpha interferon to treat lung malignancies
WO1992017209A1 (fr) 1991-04-08 1992-10-15 Sumitomo Pharmaceuticals Company, Limited Preparation solide poreuse contenant une substance proteique physiologiquement active
CA2094217A1 (en) 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH06298665A (ja) * 1993-04-14 1994-10-25 Toray Ind Inc 抗ウイルス剤
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type

Also Published As

Publication number Publication date
IL126971A (en) 2007-12-03
BR9709068A (pt) 2000-01-11
CA2253971A1 (en) 1997-11-13
EP0906119A1 (de) 1999-04-07
IL126971A0 (en) 1999-09-22
NZ332689A (en) 2000-07-28
US6361769B1 (en) 2002-03-26
CN1151841C (zh) 2004-06-02
DE69735202T2 (de) 2006-11-02
AU724689B2 (en) 2000-09-28
AU2399397A (en) 1997-11-26
CN1218408A (zh) 1999-06-02
TW482676B (en) 2002-04-11
WO1997041884A1 (en) 1997-11-13
EP0906119A4 (de) 1999-10-20
JP2000505478A (ja) 2000-05-09
ES2260791T3 (es) 2006-11-01
JP3806445B2 (ja) 2006-08-09
ID17768A (id) 1998-01-29
DE69735202D1 (de) 2006-04-13
EP0906119B1 (de) 2006-02-01

Similar Documents

Publication Publication Date Title
ATE316792T1 (de) Stimulierung wirtseigener abwehrmechanismen gegen krebs
EP0947222A3 (de) Verfahren zur Aktivierung von photoempfindlichen Mitteln
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
PT850068E (pt) Extracto lipidico com actividade anti-inflamatoria
IL138665A0 (en) Peptide factor
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
DE69418601D1 (de) Guanidinderivate mit therapeutischer wirkung
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
CA2219070A1 (en) Methods of preventing breast cancer
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
EP0906108A4 (de) Verfahren zur behandlung von herzversagen mit endothelin-antagonist.
IL113280A0 (en) Method of treating auto-immune diseases using type one interferons
ATE229981T1 (de) Glykolisierte cytokine
BR9709223A (pt) Estimulação dos mecanismos de defesa do hospedeiro contra tumores.
DE3575671D1 (de) Verwendung von saccharomyces-hefen fuer die herstellung eines arzneimittels gegen amoebiasis.
AU9139091A (en) Oral administration of alpha interferon to treat lung malignancies
GR3023645T3 (en) Treatment of liver cancer
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
ECSP972109A (es) Estimulacion de los mecanismos de defensa del huesped contra tumores
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
ECSP972107A (es) Estimulacion de los mecanismos de defensa del huesped contra estimulaciones virales
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
RU97115829A (ru) Способ лечения коклюша у детей
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906119

Country of ref document: EP

REN Ceased due to non-payment of the annual fee